Lyssikatos Joseph P 4

What Happened Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics (ELVN), sold a total of 20,000 shares on January 20, 2026 in two open-market transactions: 5,491 shares at a weighted average price of $26.37 for $144,814, and 14,509 shares at a weighted average price of $26.90 for $390,285. Total gross proceeds were approximately $535,099. These were sales (not purchases), which are generally considered routine dispositions rather than affirmative bullish signals.

Key Details

• Transaction date: January 20, 2026; Form 4 filed January 22, 2026 (appears timely).
• Reported prices and values: 5,491 @ $26.37 = $144,814; 14,509 @ $26.90 = $390,285; total ≈ $535,099.
• Execution detail: Both transactions were executed in multiple trades; reported prices are weighted averages. One set of trades ranged $25.605–$26.5928 (weighted avg $26.37); the other ranged $26.6137–$27.344 (weighted avg $26.90). The filer will provide per-trade details to the SEC or issuer upon request.
• Plan/tax notes: Sales were made pursuant to a Rule 10b5-1 trading plan adopted November 15, 2024.
• Ownership: The shares are held by The Lyssikatos Revocable Trust (12/15/2011), for which Mr. Lyssikatos is trustee. The filing excerpt does not state post-transaction beneficial ownership—see the full Form 4 for total shares owned after the sales.

Context These were pre-planned sales under a 10b5-1 plan, which typically means the trades followed a pre-set schedule or rules and may be routine. Sales reduce insider shareholdings but do not, by themselves, indicate management sentiment about the company's prospects. Retail investors should consult the full Form 4 filing for complete ownership details and per-trade prices if needed.